Consequently, combinatorial approaches targeting both MDM2 and the MAPK pathway (e.g., MEK inhibitors or RTK inhibitors) have demonstrated synergistic antitumor activity in preclinical models of dedifferentiated liposarcoma and lung adenocarcinoma, preventing the onset of resistance and promoting prolonged tumor control [36,37]. Here, MDM2 is linked to liposarcoma.